



The Open Rheumatology Journal

Content list available at: <https://openrheumatologyjournal.com>

Supplementary Material



RESEARCH ARTICLE

Patient Satisfaction with the Etanercept Biosimilar SB4 Device, Among Rheumatoid Arthritis and Spondyloarthritis Patients - A German Observational Study

Christof Maucksch¹, Peer M. Aries², Silke Zinke³ and Ulf Müller-Ladner⁴

¹Biogen GmbH, Carl-Zeiss-Ring, Ismaning, Germany

²Rheumatologie at Struenseehaus, Mörkenstraße, Hamburg, Germany

³Rheumapraxis Zinke, Hauptstraße, Berlin, Germany

⁴Kerckhoff-Klinik GmbH, Department for Rheumatology and Clinical Immunology, Benekestraße, Bad Nauheim, Germany

Article History

Received: February 21, 2020

Revised: April 29, 2020

Accepted: May 11, 2020

SUPPLEMENTARY MATERIAL

Table S1. Univariate and multivariate results of full multiple logistic regression model - Full Analysis Set.

Effect	Univariate			Multivariate		
	Odds Ratio	Lower limit	Upper limit	Odds Ratio	Lower limit	Upper limit
Age (<55 years, 55+ years)	0.85	0.47	1.53	0.83	0.29	2.37
Rheumatoid Arthritis (RA subgroup) (yes/no)	0.82	0.48	1.42	1.91	0.74	4.90
Ankylosing Spondylitis (SpA subgroup) (yes/no)	1.67	0.69	4.04	1.45	0.38	5.47
Previous med subgroup (new to bDMARD) (yes/no)	0.81	0.46	1.43	0.52	0.16	1.74
Previous injection (yes/no)	0.88	0.51	1.51	0.90	0.32	2.51
Disease duration (<6 years, 6+ years)	1.26	0.74	2.13	1.36	0.58	3.21
Remission (DAS28/BASDAI) (yes/no)	2.67	1.15	6.21	3.25	1.29	8.17
Comorbidity (yes/no)	0.94	0.55	1.59	2.02	0.87	4.69
Concomitant medication (yes/no)	1.25	0.65	2.43	1.13	0.33	3.93
Self-injection (yes/no)	2.03	0.78	5.26	1.82	0.44	7.52

RA=Rheumatoid Arthritis, SpA=Spondyloarthritis, DMARD=Disease-Modifying Antirheumatic Drug, b=Biological, DAS=Disease Activity Score, BASDAI=Bath Ankylosing Spondylitis Disease Activity Index.

© 2020 Maucksch *et al.*

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (<https://creativecommons.org/licenses/by/4.0/legalcode>). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.